Literature DB >> 25665508

Natural history of surgically treated high-risk prostate cancer.

Alberto Briganti1, Robert Jeffrey Karnes2, Giorgio Gandaglia3, Martin Spahn4, Paolo Gontero5, Lorenzo Tosco6, Burkhard Kneitz7, Felix K H Chun8, Emanuele Zaffuto3, Maxine Sun9, Markus Graefen10, Giansilvio Marchioro11, Detlef Frohneberg12, Simone Giona5, Pierre I Karakiewicz9, Hein Van Poppel6, Francesco Montorsi3, Steven Joniau6.   

Abstract

BACKGROUND: No data exist on the patterns of biochemical recurrence (BCR) and their effect on survival in patients with high-risk prostate cancer (PCa) treated with surgery. The aim of our investigation was to evaluate the natural history of PCa in patients treated with radical prostatectomy (RP) alone.
MATERIALS AND METHODS: Overall, 2,065 patients with high-risk PCa treated with RP at 7 tertiary referral centers between 1991 and 2011 were identified. First, we calculated the probability of experiencing BCR after surgery. Particularly, we relied on conditional survival estimates for BCR after RP. Competing-risks regression analyses were then used to evaluate the effect of time to BCR on the risk of cancer-specific mortality (CSM).
RESULTS: Median follow-up was 70 months. Overall, the 5-year BCR-free survival rate was 55.2%. Given the BCR-free survivorship at 1, 2, 3, 4, and 5 years, the BCR-free survival rates improved by+7.6%,+4.1%,+4.8%,+3.2%, and+3.7%, respectively. Overall, the 10-year CSM rate was 14.8%. When patients were stratified according to time to BCR, patients experiencing BCR within 36 months from surgery had higher 10-year CSM rates compared with those experiencing late BCR (19.1% vs. 4.4%; P<0.001). At multivariate analyses, time to BCR represented an independent predictor of CSM (P<0.001).
CONCLUSIONS: Increasing time from surgery is associated with a reduction of the risk of subsequent BCR. Additionally, time to BCR represents a predictor of CSM in these patients. These results might help provide clinicians with better follow-up strategies and more aggressive treatments for early BCR.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biochemical recurrence; Cancer-specific mortality; Prostate cancer; Radical prostatectomy; Time to biochemical recurrence

Mesh:

Substances:

Year:  2015        PMID: 25665508     DOI: 10.1016/j.urolonc.2014.11.018

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  31 in total

1.  (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.

Authors:  Tiziano Graziani; Francesco Ceci; Paolo Castellucci; Giulia Polverari; Giacomo Maria Lima; Filippo Lodi; Alessio Giuseppe Morganti; Andrea Ardizzoni; Riccardo Schiavina; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-08       Impact factor: 9.236

2.  Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer.

Authors:  Katharina Boehm; Paolo Dell'Oglio; Zhe Tian; Umberto Capitanio; Felix K H Chun; Derya Tilki; Axel Haferkamp; Fred Saad; Francesco Montorsi; Markus Graefen; Pierre I Karakiewicz
Journal:  World J Urol       Date:  2016-10-28       Impact factor: 4.226

Review 3.  Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer.

Authors:  Robert T Dess; Todd M Morgan; Paul L Nguyen; Rohit Mehra; Howard M Sandler; Felix Y Feng; Daniel E Spratt
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

4.  mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy.

Authors:  Samuel A Gold; David J VanderWeele; Stephanie Harmon; Jonathan B Bloom; Fatima Karzai; Graham R Hale; Shawn Marhamati; Kareem N Rayn; Sherif Mehralivand; Maria J Merino; James L Gulley; Marijo Bilusic; Ravi A Madan; Peter L Choyke; Baris Turkbey; William Dahut; Peter A Pinto
Journal:  Urol Oncol       Date:  2019-04-15       Impact factor: 3.498

Review 5.  The Impact of PSMA PET/CT Imaging in Prostate Cancer Radiation Treatment.

Authors:  Esther Mena; Liza Lindenberg; Peter Choyke
Journal:  Semin Nucl Med       Date:  2022-01-10       Impact factor: 4.446

6.  Preoperative Predictors of Lymph Node Invasion and Biochemical Recurrence in High-risk Prostate Cancer.

Authors:  Yohei Shida; Tomoaki Hakariya; Kensuke Mitsunari; Tomohiro Matsuo; Kojiro Ohba; Yasuyoshi Miyata; Hideki Sakai
Journal:  Cancer Diagn Progn       Date:  2022-01-03

7.  Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy.

Authors:  Esther Mena; Maria L Lindenberg; Joanna H Shih; Stephen Adler; Stephanie Harmon; Ethan Bergvall; Deborah Citrin; William Dahut; Anita T Ton; Yolanda McKinney; Juanita Weaver; Philip Eclarinal; Alicia Forest; George Afari; Sibaprasad Bhattacharyya; Ronnie C Mease; Maria J Merino; Peter Pinto; Bradford J Wood; Paula Jacobs; Martin G Pomper; Peter L Choyke; Baris Turkbey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-09-11       Impact factor: 9.236

Review 8.  The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer.

Authors:  Giorgio Gandaglia; Cesare Cozzarini; Alexandre Mottrie; Alberto Bossi; Nicola Fossati; Francesco Montorsi; Alberto Briganti
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

9.  Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.

Authors:  Pietro Ghedini; I Bossert; L Zanoni; F Ceci; T Graziani; P Castellucci; V Ambrosini; F Massari; E Nobili; B Melotti; A Musto; S Zoboli; L Antunovic; M Kirienko; A Chiti; C Mosconi; A Ardizzoni; R Golfieri; S Fanti; C Nanni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-30       Impact factor: 9.236

Review 10.  Seek and Find: Current Prospective Evidence for Prostate-specific Membrane Antigen Imaging to Detect Recurrent Prostate Cancer.

Authors:  Niamh M Keegan; Lisa Bodei; Michael J Morris
Journal:  Eur Urol Focus       Date:  2021-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.